// App-Quantinova.ai

1757 : Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Researchers

Presenter

  • Adrian Newland

Principal Investigators

  • Howard A. Liebman

  • Vickie McDonald

  • Marc Michel

  • Yoshitaka Miyakawa

  • Wim Parys

  • Hans De Haard

  • Peter Ulrichts

  • Marie Godar

  • Kristof De Beuf

  • Jaume Ayguasanosa

  • Catherine M Broome

  • David J. Kuter

Medical Centers

  • Barts and the London School of Medicine, London, United Kingdom

  • Jane Anne Nohl Division of Hematology, USC Norris Cancer Hospital, Los Angeles, CA

  • Clinical Haematology, Barts Health NHS Trust &Queen Mary University, London, UK, London, United Kingdom

  • Hôpital Henri Mondor, Créteil, France,

  • Thrombosis and Hemostasis Center,Saitama Medical University Hospital,Saitama,Japan

  • argenx, Boston, MA

  • argenx BVBA, Zwijnaarde, Belgium

  • argenx,Ghent,België

  • Division of Rheumatology, The George Washington University, Washington, DC

  • Nephrology Division, Massachusetts General Hospital, Boston, MA

Locations

  • United Kingdom

  • United States

  • France

  • Japan

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • N/A

Drug/Treatment

  • Eltrombopag

  • Danazol

  • Dapsone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Pharmacodynamics

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03102593

  • NCT04188379

  • NCT04225156

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved